Niagen Bioscience (NAGE) Asset Writedowns and Impairment (2016 - 2026)
Niagen Bioscience (NAGE) reported Asset Writedowns and Impairment of $85000.0 for Q1 2026, up 106.43% year-over-year from $41175.3 in Q1 2025, and up 214.81% quarter-over-quarter from $27000.0 in Q4 2025.
Niagen Bioscience (NAGE) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 11 years of Asset Writedowns and Impairment data on file, last reported at $85000.0 in Q1 2026.
- Asset Writedowns and Impairment for Q1 2026 came in at $85000.0, up 106.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $189000.0 (up 107.24% YoY), and the FY2025 annual result was -$1.2 million, up 3.03% from the prior year.
- Asset Writedowns and Impairment climbed to $85000.0 in Q1 2026 per NAGE's latest filing, from $27000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $400000.0 in Q2 2023 and troughed at -$1.3 million in Q1 2025.
- A 5-year average of -$81705.9 and a median of $23000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment soared 8100.0% in 2023, then slumped 7015.79% in 2024.
- A 5-year view of Asset Writedowns and Impairment shows it stood at $35000.0 in 2022, then tumbled by 45.71% to $19000.0 in 2023, then tumbled by 7015.79% to -$1.3 million in 2024, then soared by 102.05% to $27000.0 in 2025, then soared by 214.81% to $85000.0 in 2026.
- Business Quant data shows NAGE's Asset Writedowns and Impairment at $85000.0 in Q1 2026, $27000.0 in Q4 2025, and -$12000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Niagen Bioscience | 277.31 Mn | 210.76 Mn | 19.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 85,000.00 |
| Mar 31, 2026 | 85,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Dec 31, 2025 | 27,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Sep 30, 2025 | -12,000.00 |
| Jun 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 89,000.00 |
| Mar 31, 2025 | -1.32 Mn |
| Mar 31, 2025 | -1.32 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Dec 31, 2024 | -1.31 Mn |
| Sep 30, 2024 | 12,000.00 |
| Sep 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |